The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Nevirapine and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis
Abstract
OBJECTIVE: To draw attention to the many cases of Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) related to nevirapine detected in a multinational case-control study of SJS and TEN. METHODS: Actively detected cases and matched hospital controls were interviewed for exposure to drugs and other risk factors. Data were analysed with case-control and case-crossover methods. RESULTS: Between May 1997 and November 1999, a diagnosis of SJS or TEN was established in 246 patients. Eighteen were known to be infected by HIV-1 (7.3%), 15 out of these 18 had been exposed to nevirapine. The reaction began 10-240 days after the introduction of nevirapine (median, 12 days) and all patients had received escalating doses. In 10 patients the reaction occurred with the initial dosage. All but one patients received simultaneously a variety of other antiretroviral agents but no specific drug combination emerged, and nevirapine was the only drug significantly associated with an increased risk of SJS or TEN in HIV-infected persons [odds ratio, 62 (10.4; +infinity) in the case-control analysis; odds ratio, +infinity (2.8; +infinity) in the case-crossover analysis]. CONCLUSIONS: In European countries the risk of SJS or TEN in the context of HIV infection appears to be associated with nevirapine. The respect of a lead-in period does not appear to prevent SJS or TEN. Because of the severity of these reactions and the long elimination half-life of nevirapine, we suggest discontinuation of the drug as soon as any eruption occurs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Case-Crossover Design: A Method for Studying Transient Effects on the Risk of Acute Events
Maclure, M. (1991) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115853 · Cited by 2,327
Cited by
Mockenhaupt, M., Viboud, C., Dunant, A., Naldi, L., Halevy, S., Bavinck, J. N. B., Sidoroff, A., Schneck, J., Roujeau, J.-C., & Flahault, A. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701033 · Cited by 1,017
Self-citationLonjou, C., Borot, N., Sekula, P., Ledger, N., Thomas, L., Halevy, S., Naldi, L., Bouwes-Bavinck, J.-N., Sidoroff, A., de Toma, C., et al. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f3ef9c · Cited by 624
Self-citationSulkowski, M. S., Thomas, D. L., Mehta, S. H., Chaisson, R. E., & Moore, R. D. (2002) · Hepatology · doi:10.1053/jhep.2002.30319 · Cited by 523
Dybul, M., Fauci, A. S., Bartlett, J. G., Kaplan, J. E., & Pau, A. K. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-5_part_2-200209031-00001 · Cited by 482
A marker for Stevens-Johnson syndrome …: ethnicity matters
Lonjou, C., Thomas, L., Borot, N., Ledger, N., de Toma, C., LeLouet, H., Graf, E., Schumacher, M., Hovnanian, A., Mockenhaupt, M., et al. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500356 · Cited by 401
Self-citation
Metadata
- Authors
- Fagot, J.-P., Mockenhaupt, M., Bouwes-Bavinck, J.-N., Naldi, L., Viboud, C., & Roujeau, J.-C.
- Venue
- AIDS
- Published
- 2001-09
- Volume
- 15
- Issue
- 14
- Pages
- 1843-1848
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W3042812874
- Cited by
- 200
- References
- 1
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nevirapine and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. https://app.cochat.ai/papers/10.1097/00002030-200109280-00014
- The paper
- Fagot, J.-P., Mockenhaupt, M., Bouwes-Bavinck, J.-N., Naldi, L., Viboud, C., & Roujeau, J.-C. (2001). Nevirapine and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. AIDS. https://doi.org/10.1097/00002030-200109280-00014
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.